Esaxerenone is an oral, nonsteroidal, selective mineralocorticoid receptor blocker,7, 8, 9, 10 which was approved in Japan in January 2019 for the treatment of hypertension.11 This evidence concerns the gene NR3C2 and hypertensive disorder.